-
2025-523586-18-00
5
Non-Small Cell Lung Cancer
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-520740-16-00
5
2025-09-19
Primary Aldosteronism defined by excess aldosterone secretion
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2025-521912-21-00
4
2026-01-26
Cardiovascular risk reduction in participants with elevated Lp(a)
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2022-502781-24-01
5
2024-06-05
ASCVD - Atherosclerotic Cardiovascular Disease
-
2023-506988-34-00
5
2024-03-27
Heart failure with mildly reduced or preserved ejection fraction and s
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H